期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2012年11月FDA批准新药概况 被引量：5

下载PDF
导出
摘要 2012年11月，FDA批出2个新分子实体药品（表1），分别为治疗类风湿关节炎药品Xelianz、治疗转移性甲状腺髓样癌药品Cometriq。
作者 张建忠
出处 《上海医药》 CAS 2013年第1期61-61,共1页 Shanghai Medical & Pharmaceutical Journal
关键词 FDA批准 新药 类风湿关节炎 甲状腺髓样癌 新分子实体 药品 转移性 治疗
分类号 R95 [医药卫生—药学]
  • 相关文献

同被引文献41

  • 1Burmester GR, Blanco R, Schoeman CC, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial [J]. Lancet, 2013, 381 (9865): 451-460.
  • 2Brown Ripin DH, Abele S, Cai WL, et al. Development of a scaleable route for the production of cis-N-benzyl-3- methylamino-4-methylpiperidine [J]. Org Process Res Dev, 2003, 7(1) : 115-120.
  • 3Rao TS, Zhang C. Deuterated tasocitinib derivatives as Janus kinase 3 inhibitors and their preparation and use for the treatment and prevention of Janus kinase 3-mediated diseases: WO, 2010123919 EP]. 2010-10-28. (CA 2010, 153: 555186).
  • 4Cai WL, Colony JL, Frost H, et al. Investigation of practical routes for the kilogram-scale production of cis-3- methylamino-4-methylpiperidines [J]. Org Process Res Dev, 2005, 9(1): 51-56.
  • 5Yarlagadda BS, Pooran C. Preparation of piperidine derivatives as immune suppressant for the treatment of diseases associated with pathologic JAK3 activation: WO, 2010014930 [P]. 2010-02-04. (CA2010, 152: 215329).
  • 6Andrew BT, Edward FM, John MM. Synthesis of pyrrolo [2,3-d] pyrimidine compounds as inhibitors of protein kinases: WO, 0142246 P. 2001-06-14. (CA 2001, 135: 46193).
  • 7Gut RS, Michael H J, Margaret MT, et al. Process for preparation of piperidinylamino pyrrolo- pyrimidines from activated pyrrolopyrimidines and piperidinylamines: WO, 2007012953 [P]. 2007-02-01. (CA 2007, 146: 206328).
  • 8Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus Kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection [J]. J ivied Chem, 2010, 53 (24) : 8468-8484.
  • 9Jiang JK, Ghoreschi K, Deflorian F, et al. Examining the chirality, conformation and selective kinase inhibition of 3- ((3R,4R) -4-methyl-3- (methyl (7H- pyrrolo [2,3- d] pyrimidin-4-yl) amino) piperidin- 1-yl) -3-oxopropanenitrile (CP-690,550) [J]. JMed Chem, 2008, 51 (24) : 8012-8018.
  • 10Kasat RB, Wang NH, Franses EI. Experimental probing and modeling of key sorbent-solute interactions of norephedrine enantiomers with polysaccharide-based chiral stationary phases [J]. J Chromatogr A, 2008, 1190 (1-2) : 110-119.

引证文献5

二级引证文献15

上海医药
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部